Research map: Complex Karyotype and TP53 Alterations in AML and MDS

Back to the article

Papers in this map

  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms · Joseph David Khoury · 2022 · 4220 citations · Cited by this paper
  2. Flow Cytometry Immunophenotyping in Hematology Clinical Practice: Panacea or a Diagnostic Tool? Conclusions from a Case Report · 2026 · Related
  3. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN · Hartmut Döhner · 2022 · 3298 citations · Cited by this paper
  4. Genome-Wide CRISPR-Cas9 Knockout Screening Identifies NUDCD2 Depletion as Sensitizer for Bortezomib, Carfilzomib and Ixazomib in Multiple Myeloma · 2025 · Related
  5. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data · Daniel A. Arber · 2022 · 2919 citations · Cited by this paper
  6. Persistent Remission of Angioimmunoblastic T-Cell Lymphoma and Associated Immune-Mediated Thrombotic Thrombocytopenic Purpura After Multimodal Therapy: A Case Report · 2026 · Related
  7. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development · Philip J. Stephens · 2011 · 2500 citations · Cited by this paper
  8. Comparative Analysis of Erythrocyte Morphology in Hematological Malignancies and Anemia · 2026 · Related
  9. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia · Terrence Neal Wong · 2014 · 901 citations · Cited by this paper
  10. Primary Small Bowel MALT Lymphoma with Concurrent Pulmonary Dissemination: A Case Report · 2026 · Related
  11. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations · Tobias Rausch · 2012 · 891 citations · Cited by this paper
  12. Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia · 2026 · Related
  13. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes · John Sutton Welch · 2016 · 801 citations · Cited by this paper
  14. Cytogenetics and genomics of acute myeloid leukemia · 2023 · Related
  15. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome · Frank G. Rücker · 2011 · 696 citations · Cited by this paper
  16. High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China · 2024 · Related
  17. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes · Elsa Bernard · 2020 · 660 citations · Cited by this paper
  18. Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study · 2026 · Related
  19. Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype · Dimitri A. Breems · 2008 · 585 citations · Cited by this paper
  20. Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics · 2026 · Related
  21. Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes · David Andrew Sallman · 2021 · 473 citations · Cited by this paper
  22. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies · Steffen Boettcher · 2019 · 449 citations · Cited by this paper
  23. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells · Tamilla Nechiporuk · 2019 · 381 citations · Cited by this paper
  24. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation · Tetsuichi Yoshizato · 2017 · 359 citations · Cited by this paper
  25. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome · Tim Grob · 2022 · 305 citations · Cited by this paper
  26. Eprenetapopt Plus Azacitidine in TP53 -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) · Thomas Cluzeau · 2021 · 277 citations · Cited by this paper
  27. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups · Detlef Haase · 2019 · 264 citations · Cited by this paper
  28. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients · Betül Oran · 2020 · 221 citations · Cited by this paper
  29. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis · David Bowen · 2008 · 216 citations · Cited by this paper
  30. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML · Olga K. Weinberg · 2022 · 200 citations · Cited by this paper
  31. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia · Hans‐Helge Seifert · 2009 · 160 citations · Cited by this paper
  32. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine · Daniel Aaron Pollyea · 2022 · 156 citations · Cited by this paper
  33. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes · Guillermo Montalban Bravo · 2020 · 135 citations · Cited by this paper
  34. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial · Nicholas James Short · 2018 · 121 citations · Cited by this paper
  35. Chromothripsis in acute myeloid leukemia: biological features and impact on survival · Maria Chiara Fontana · 2018 · 116 citations · Cited by this paper
  36. Karyotype complexity and prognosis in acute myeloid leukemia · Friedrich Stölzel · 2016 · 111 citations · Cited by this paper
  37. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status · Alfonso Quintás‐Cardama · 2016 · 111 citations · Cited by this paper
  38. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically · Krzysztof Mrózek · 2019 · 91 citations · Cited by this paper
  39. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype · Mrinal M. Patnaik · 2010 · 85 citations · Cited by this paper

Source: OpenAlex (CC0)